Suppr超能文献

可溶性受体与结合蛋白的故事:从实验室到临床

The tale of soluble receptors and binding proteins: from bench to bedside.

作者信息

Novick Daniela, Rubinstein Menachem

机构信息

Department of Molecular Genetics, The Weizmann Institute of Science, Rehovot 76100, Israel.

出版信息

Cytokine Growth Factor Rev. 2007 Oct-Dec;18(5-6):525-33. doi: 10.1016/j.cytogfr.2007.06.024. Epub 2007 Jul 30.

Abstract

Our approach of isolating proteins from a rich source of human proteins by ligand-affinity-chromatography enabled rapid and efficient isolation of not only soluble receptors corresponding to cell-associated receptors, but also independent binding-proteins and associated enzymes. No other approach would yield the latter. During the early 80's we prepared the tools and the infrastructure that enabled the subsequent 20 years of achievements. Thus we described eight soluble receptors (R) and binding proteins (BP) for various cytokines including the IL-6R, IFN-gammaR, TNFRI, TNFRII, LDLR, IFN-alpha/betaR, IL-18BP and IL-32BP identified as Proteinase 3. The isolation of the soluble IFN-alpha/beta receptor led to the cloning of its long sought cell surface ligand binding counterpart. We have established the concept that soluble receptors and binding proteins are normal constituents of body fluids in healthy individuals and that the levels of these biomarkers are modulated in various pathological situations. Each of these proteins contributed to basic science, one of them serves as a basis for therapy and some others are in various stages of clinical development.

摘要

我们通过配体亲和色谱法从丰富的人类蛋白质来源中分离蛋白质的方法,不仅能够快速有效地分离与细胞相关受体相对应的可溶性受体,还能分离出独立的结合蛋白和相关酶。其他方法都无法得到后者。在80年代早期,我们制备了工具和基础设施,促成了随后20年的成果。因此,我们描述了八种针对各种细胞因子的可溶性受体(R)和结合蛋白(BP),包括白细胞介素-6受体(IL-6R)、干扰素-γ受体(IFN-γR)、肿瘤坏死因子受体I(TNFRI)、肿瘤坏死因子受体II(TNFRII)、低密度脂蛋白受体(LDLR)、干扰素-α/β受体(IFN-α/βR)、白细胞介素-18结合蛋白(IL-18BP)以及被鉴定为蛋白酶3的白细胞介素-32结合蛋白(IL-32BP)。可溶性干扰素-α/β受体的分离导致了其长期寻找的细胞表面配体结合对应物的克隆。我们已经确立了这样的概念,即可溶性受体和结合蛋白是健康个体体液中的正常成分,并且这些生物标志物的水平在各种病理情况下会发生调节。这些蛋白质中的每一种都对基础科学有贡献,其中一种作为治疗的基础,其他一些则处于临床开发的不同阶段。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验